00:30
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial is a landmark study that, along with a rapidly growing body of evidence, has firmly established SGLT2 inhibition as new standard of care for people with type 2 diabetes and chronic kidney disease.1,2 (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))
00:30[Articles] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial -
Hiddo J L Heerspink, Niels Jongs, Glenn M Chertow, Anna Maria Langkilde, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, David C Wheeler, Tom Greene, DAPA-CKD Trial Committees and Investigators
Lancet Diab Endocrinol
Dapagliflozin significantly slowed long-term eGFR decline in patients with chronic kidney disease compared with placebo. The mean difference in eGFR slope between patients treated with dapagliflozin versus placebo was greater in patients with type 2 diabetes, higher HbA1c, and higher (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))
00:30[Articles] Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial -
Niels Jongs, Tom Greene, Glenn M Chertow, John J V McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, David C Wheeler, Hiddo J L Heerspink, DAPA-CKD Trial Committees and Investigators
Lancet Diab Endocrinol
In patients with chronic kidney disease with and without type 2 diabetes, dapagliflozin significantly reduced albuminuria, with a larger relative reduction in patients with type 2 diabetes. The similar effects of dapagliflozin on clinical outcomes in patients with or without type 2 diabetes, (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))
00:30[Review] COVID-19 and metabolic disease: mechanisms and clinical management -
Charlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, Andreas Linkermann, Paul Zimmet, Konstantin Kulebyakin, Vsevolod A Tkachuk, Alexander G Markov, Hendrik Lehnert, Martin Hrab? de Angelis, Hannes Rietzsch, Roman N Rodionov, Kamlesh Khunti, David Hopkins, Andreas L Birkenfeld, Bernhard Boehm, Richard I G Holt, Jay S Skyler, J Hans DeVries, Eric Renard, Robert H Eckel, K George M M Alberti, Bruno Geloneze, Juliana C Chan, Jean Claude Mbanya, Henry C Onyegbutulem, Ambady Ramachandran, Abdul Basit, Mohamed Hassanein, Gavin Bewick, Giatgen A Spinas, Felix Beuschlein, Rüdiger Landgraf, (...)
Lancet Diab Endocrinol
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver (...) (The Lancet Diabetes & Endocrinology 9, 11 (2021))